Your session is about to expire
← Back to Search
Zenocutuzumab for Non-Small Cell Lung and Prostate Cancers
Study Summary
This trial tests a new drug to treat lung and prostate cancers.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My blood counts and organ functions are within the required ranges.I do not have active hepatitis B, untreated hepatitis C, or HIV.I had a heart attack less than 6 months ago.I am using birth control if I can have children and am sexually active.I have serious heart issues, but not atrial fibrillation or brief, sudden heart palpitations.I take more than 10 mg of prednisone or similar medication daily.I have not had any other cancers in the last 3 years.My brain metastases are either untreated, causing symptoms, or need ongoing treatment.I am fully active or can carry out light work.I am 18 years old or older.I do not have any serious illness or uncontrolled infections.I can provide a recent or fresh tumor sample for the study.My cancer has spread to the lining of my brain and spinal cord.I have been treated with anti-HER3 therapies before.My blood pressure is not higher than 150/100 mmHg and I don't have unstable chest pain.
- Group 1: Part 1: mCRPC
- Group 2: Part 1: NSCLC harboring NRG1+ fusion
- Group 3: Part 2: NSCLC harboring NRG1+ fusion
- Group 4: Part 2: mCRPC
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What risks can be associated with mCRPC Phase 1?
"Although there is some evidence of safety, no clinical data exists regarding Part 1: mCRPC efficacy. Thus, it scored a 2 on our team's scale ranging from 1 to 3."
How many participants have signed up for involvement in this research?
"Affirmative, the information available from clinicaltrials.gov specifies that this scientific trial is still recruiting volunteers to participate. It was first posted on November 17th 2022 and its data set has been updated most recently on the 21st of November 2022. The research necessitates 90 participants at a single site."
What is the purpose of this experiment?
"This clinical trial seeks to assess the efficacy, safety and tolerability of Zenocutuzumab in combination with Afatinib over a two year period. Primary measurements include response rate, frequency/nature of adverse events (CTCAE Version 5.0), Area Under Curve (AUC0-∞) for afatinib and Progression-Free Survival (PFS) per RECIST v1.1 as determined by local investigators."
Are there any opportunities currently available to participate in this research?
"Affirmative. According to the information provided on clinicaltrials.gov, this investigation is actively searching for participants and was initially posted on November 17th 2022 with a most recent update occurring four days later."
Share this study with friends
Copy Link
Messenger